Channelpedia

PubMed 25867067


Referenced in Channelpedia wiki pages of: none

Automatically associated channels: SK1 , TRP , TRPV , TRPV4



Title: Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy.

Authors: R K Adapala, R J Thoppil, K Ghosh, H C Cappelli, A C Dudley, S Paruchuri, V Keshamouni, M Klagsbrun, J G Meszaros, W M Chilian, D E Ingber, C K Thodeti

Journal, date & volume: Oncogene, 2015 Apr 13 , ,

PubMed link: http://www.ncbi.nlm.nih.gov/pubmed/25867067


Abstract
Tumor vessels are characterized by abnormal morphology and hyperpermeability that together cause inefficient delivery of chemotherapeutic agents. Although vascular endothelial growth factor has been established as a critical regulator of tumor angiogenesis, the role of mechanical signaling in the regulation of tumor vasculature or tumor endothelial cell (TEC) function is not known. Here we show that the mechanosensitive ion channel transient receptor potential vanilloid 4 (TRPV4) regulates tumor angiogenesis and tumor vessel maturation via modulation of TEC mechanosensitivity. We found that TECs exhibit reduced TRPV4 expression and function, which is correlated with aberrant mechanosensitivity towards extracellular matrix stiffness, increased migration and abnormal angiogenesis by TEC. Further, syngeneic tumor experiments revealed that the absence of TRPV4 induced increased vascular density, vessel diameter and reduced pericyte coverage resulting in enhanced tumor growth in TRPV4 knockout mice. Importantly, overexpression or pharmacological activation of TRPV4 restored aberrant TEC mechanosensitivity, migration and normalized abnormal angiogenesis in vitro by modulating Rho activity. Finally, a small molecule activator of TRPV4, GSK1016790A, in combination with anticancer drug cisplatin, significantly reduced tumor growth in wild-type mice by inducing vessel maturation. Our findings demonstrate TRPV4 channels to be critical regulators of tumor angiogenesis and represent a novel target for anti-angiogenic and vascular normalization therapies.